A single-center, single-sequence, open-label, two-period study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of the combination of multiple doses of ralmitaront with a single dose of risperidone in healthy subjects
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Ralmitaront (Primary) ; Risperidone
- Indications Psychiatric disorders; Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Roche
Most Recent Events
- 14 Apr 2022 Status changed from active, no longer recruiting to completed.
- 09 Nov 2021 New trial record
- 01 Nov 2021 Status changed from recruiting to active, no longer recruiting.